Teunissen M W, Spoelstra P, Koch C W, Weeda B, van Duyn W, Janssens A R, Breimer D D
Br J Clin Pharmacol. 1984 Nov;18(5):707-15. doi: 10.1111/j.1365-2125.1984.tb02533.x.
The effect of liver cirrhosis on plasma clearance and metabolite profile of i.v. administered antipyrine was studied in 23 patients with alcoholic liver cirrhosis (age 37-70 years) and 17 healthy subjects (age 28-55 years). Liver volume was also measured and was found to be larger in patients than in controls, mean values being 1.86 and 1.36 l respectively. The elimination half-life of antipyrine in patients with alcoholic liver cirrhosis was significantly longer than in the healthy subjects (P less than 0.001). Mean values were 39.9 and 10.1 h respectively. Alcoholic liver cirrhosis had no effect on the apparent volume of distribution of antipyrine, but antipyrine plasma clearance was substantially reduced in the patients. Mean clearance values (ranges) were 13.5 (9.3-22.8) ml/min in the patients and 49.3 (31.1-103) ml/min in healthy subjects. Normalization of antipyrine plasma clearance for liver volume resulted in an only slightly increased distinction between patients and healthy subjects, mean values (ranges) being 7.8 (3.3-13.0) ml min(-1) 1(-1) and 36.1 (21.9-35.9) ml min(-1) 1(-1) respectively. The cumulative renal excretion of 4-hydroxyantipyrine (OHA) and norantipyrine (NORA) was significantly lower in patients with alcoholic liver cirrhosis than in healthy subjects, as was the total recovery of antipyrine and major metabolites from urine. Mean values were 15.0, 8.4 and 41.2% of dose in the patients respectively and 24.3, 25.8 and 68.9% of dose in the control subjects. Excreted amounts of total and unconjugated 3-hydroxymethylantipyrine (HMA) and of unchanged antipyrine were the same in the two groups.(ABSTRACT TRUNCATED AT 250 WORDS)
在23例酒精性肝硬化患者(年龄37 - 70岁)和17名健康受试者(年龄28 - 55岁)中研究了肝硬化对静脉注射安替比林的血浆清除率和代谢物谱的影响。同时测量了肝脏体积,发现患者的肝脏体积大于对照组,平均值分别为1.86升和1.36升。酒精性肝硬化患者中安替比林的消除半衰期显著长于健康受试者(P小于0.001)。平均值分别为39.9小时和10.1小时。酒精性肝硬化对安替比林的表观分布容积没有影响,但患者的安替比林血浆清除率大幅降低。患者的平均清除率值(范围)为13.5(9.3 - 22.8)毫升/分钟,健康受试者为49.3(31.1 - 103)毫升/分钟。根据肝脏体积对安替比林血浆清除率进行标准化后,患者与健康受试者之间的差异仅略有增加,平均值(范围)分别为7.8(3.3 - 13.0)毫升·分钟⁻¹·升⁻¹和36.1(21.9 - 35.9)毫升·分钟⁻¹·升⁻¹。酒精性肝硬化患者中4 - 羟基安替比林(OHA)和去甲安替比林(NORA)的累积肾排泄量显著低于健康受试者,安替比林及其主要代谢物从尿液中的总回收率也是如此。患者的平均值分别为剂量的15.0%、8.4%和41.2%,对照组受试者为剂量的24.3%、25.8%和68.9%。两组中总3 - 羟甲基安替比林(HMA)和未结合的3 - 羟甲基安替比林以及未改变的安替比林的排泄量相同。(摘要截短于250字)